Last Update 21 Mar 26

Fair value Increased 6.41%

REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks

Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple.

Analyst Commentary

Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price. For you as an investor, the debate largely centers on execution around key drugs, the durability of cash flows, and how much to pay for that profile through the cycle.

Bullish Takeaways

Bullish analysts argue that the market is underpricing Dupixent's profit contribution over the near and medium term, which they see as supportive of higher fair value estimates than current trading levels suggest.
Several recent price target increases, including moves toward the high US$800s and low US$900s, are linked to the view that the pipeline, including assets such as Lynozyfic, is not fully reflected in current valuations.
Dupixent indication expansion is seen by bullish analysts as an underappreciated growth tailwind, with potential to support revenue durability and justify premium multiples even as the company matures.
Some large firms, including Goldman Sachs, have lifted price targets meaningfully, which reinforces the idea that, in their view, execution on existing franchises and the R&D engine can support more optimistic scenarios than the market is currently pricing.

Bearish Takeaways

More cautious analysts highlight that, despite a constructive view on the R&D engine and Dupixent, the shares can trade at a discount because of Eylea headwinds, which create uncertainty around a key revenue contributor.
There is concern around Dupixent loss of exclusivity, with some bearish analysts flagging that uncertainty as a reason the stock may struggle to sustain higher P/E multiples even with strong fundamentals.
The clustering of price target increases around similar ranges suggests that, while sentiment is generally positive, some of the upside case may already be reflected, leaving less room for error on execution or clinical outcomes.
Where price targets are raised but ratings remain more neutral, it signals that certain analysts see fair value closer to current levels, limiting the margin of safety if the company underdelivers against expectations on Dupixent or pipeline milestones.

What's in the News

Dupixent receives U.S. FDA approval for adults and children 6 years and older with allergic fungal rhinosinusitis, expanding approved sino nasal indications beyond chronic rhinosinusitis with nasal polyps and supported by the LIBERTY AFRS AIMS Phase 3 trial, which showed improvements in sinus opacification, nasal congestion, polyp size, sense of smell and reduced need for surgery or systemic steroids (Key Developments).
The European Medicines Agency’s CHMP adopts a positive opinion recommending Dupixent approval in the EU for children 2 to 11 years with moderate to severe chronic spontaneous urticaria who have inadequate response to antihistamines and are naïve to anti IgE therapy, with the opinion backed by multiple Phase 3 LIBERTY CUPID trials (Key Developments).
Japan’s Ministry of Health, Labour and Welfare grants marketing and manufacturing authorization for Dupixent to treat severe or refractory bronchial asthma in children 6 to 11 years whose symptoms are not adequately controlled with existing therapy (Key Developments).
The U.S. FDA accepts Regeneron’s Biologics License Application for garetosmab for adults with fibrodysplasia ossificans progressiva, granting Priority Review based on Phase 3 OPTIM data in which both doses reduced the total number of new heterotopic ossification lesions compared with placebo. An FDA action date is targeted for August 2026 (Key Developments).
Regeneron reports a quarterly dividend of US$0.94 per share, payable on March 5, 2026, and confirms completion of a share repurchase tranche. The company bought back 2,536,183 shares, representing 2.45% of shares, for US$1,510.61m under a program announced on February 4, 2025 (Key Developments).

Valuation Changes

Fair Value: The modelled fair value estimate has increased from $821.12 to $873.78 per share, representing a moderate step up in implied equity value.
Discount Rate: The discount rate has risen slightly from 7.07% to 7.13%, indicating a small increase in the required return used in the model.
Revenue Growth: The assumed revenue growth rate has shifted from 7.20% to 9.20%, reflecting a higher modelled top-line growth outlook.
Net Profit Margin: The forecast net profit margin has been raised from 30.30% to 32.28%, implying a modestly higher level of expected earnings efficiency.
Future P/E: The assumed future P/E multiple has edged lower from 17.06x to 16.75x, pointing to a slightly more conservative valuation multiple being applied.

35 views

Key Takeaways

Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings.
Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.
Heavy reliance on EYLEA amid intensifying competition, regulatory delays, and pricing pressures threatens revenue sustainability, while pipeline and market uncertainties cloud future growth prospects.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

Regeneron's broad and advancing pipeline-including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity-positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Rapid growth and expansion of Dupixent (with new indications in COPD, CSU, and bullous pemphigoid) has significantly increased the addressable patient population, but only a small fraction of eligible patients are currently being treated, leaving substantial runway for volume growth, especially as global healthcare access expands-supportive of higher long-term revenues and margins.
The successful ramp of EYLEA HD, which is gaining physician adoption due to its clinical profile and durability, along with anticipated regulatory approvals for label enhancements (pending resolution of manufacturing site issues), could help offset patent/biosimilar pressures on legacy EYLEA, supporting stabilization and potential growth in core revenue and sustaining healthy margins over the next several years.
Significant reinvestment in internal R&D, advanced manufacturing, and in-house biologics and gene therapy platforms provides Regeneron with cost advantages and rapid scalability, enhancing margin protection as the industry accelerates adoption of new biotechnologies (AI, big data, CRISPR) and as regulatory pathways become more favorable for differentiated breakthrough therapies.
Expansion into high-growth indications such as obesity and cardiometabolic diseases (via GLP-1/GIP, novel antibody combinations) and strategic development for emerging market access (benefiting from increased global healthcare spending) create new multi-billion-dollar revenue streams likely underappreciated by the market, supporting higher long-term earnings and revenue diversification.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 9.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 31.4% today to 32.3% in 3 years time.
Analysts expect earnings to reach $6.0 billion (and earnings per share of $55.81) by about March 2029, up from $4.5 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $7.3 billion in earnings, and the most bearish expecting $5.0 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.8x on those 2029 earnings, up from 16.7x today. This future PE is greater than the current PE for the US Biotechs industry at 16.7x.
Analysts expect the number of shares outstanding to decline by 2.7% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.13%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

EYLEA faces ongoing branded and biosimilar competition as well as continued unit demand declines, with management explicitly cautioning that pricing, patient affordability issues, and competitive pressures are expected to negatively impact future U.S. net product sales; this poses a risk of significant revenue and earnings erosion as EYLEA represents a large portion of current revenue.
Delays in regulatory approvals for EYLEA HD enhancements-due to FDA observations at key third-party manufacturing sites (Catalent/Novo Nordisk Indiana)-create near-term uncertainty and may postpone critical product improvements and label expansions essential to offset competitive headwinds, pressuring near
to long-term revenue and margin growth.
The company is significantly increasing internal R&D and U.S. manufacturing investments (over $7 billion), but with pipeline skepticism from analysts regarding the commercial value of late-stage assets relative to high annual R&D spend, there is risk of insufficient pipeline diversification or failure to generate new blockbusters, potentially limiting future earnings growth and compressing net margins.
External policy and pricing risks such as Medicare's MFN (Most Favored Nation) pricing, increased global pressure on drug prices, and uncertainty around reimbursement-particularly for key U.S. products like EYLEA-could compress net selling prices and reduce overall revenue and margins, especially if Regeneron cannot influence pricing in OUS (outside U.S.) markets managed by partners like Bayer.
The branded anti-VEGF market is experiencing share erosion to lower-cost alternatives (e.g., Avastin) due to patient affordability and assistance funding gaps, while ongoing and heightened biosimilar competition further threaten market share for established franchises, putting long-term revenue and operating income under sustained downward pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $873.78 for Regeneron Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1057.0, and the most bearish reporting a price target of just $730.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $18.7 billion, earnings will come to $6.0 billion, and it would be trading on a PE ratio of 16.8x, assuming you use a discount rate of 7.1%.
Given the current share price of $732.87, the analyst price target of $873.78 is 16.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead